Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.19
(-0.39%)
CNY 20.19
(-0.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.09 Billion CNY | 26.71% |
| 2022 | 1.65 Billion CNY | 43.15% |
| 2021 | 1.15 Billion CNY | 41.2% |
| 2020 | 818.26 Million CNY | 221.84% |
| 2019 | 254.24 Million CNY | 478.47% |
| 2018 | -67.17 Million CNY | -2.32% |
| 2017 | -65.65 Million CNY | 73.31% |
| 2016 | -245.98 Million CNY | -160.66% |
| 2015 | 405.51 Million CNY | 55.28% |
| 2014 | 261.15 Million CNY | 11265.72% |
| 2013 | 2.29 Million CNY | 100.73% |
| 2012 | -315.02 Million CNY | 46.0% |
| 2011 | -583.39 Million CNY | -810.76% |
| 2010 | 82.08 Million CNY | 47.32% |
| 2009 | 55.71 Million CNY | -25.23% |
| 2008 | 74.52 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.71 Billion CNY | -18.19% |
| 2024 Q2 | 2.24 Billion CNY | 30.84% |
| 2024 Q3 | 1.32 Billion CNY | -40.76% |
| 2023 Q4 | 2.09 Billion CNY | -2.29% |
| 2023 Q3 | 2.14 Billion CNY | 3.32% |
| 2023 FY | 2.09 Billion CNY | 26.71% |
| 2023 Q2 | 2.07 Billion CNY | 7.28% |
| 2023 Q1 | 1.93 Billion CNY | 17.0% |
| 2022 Q3 | 1.73 Billion CNY | 0.68% |
| 2022 Q2 | 1.72 Billion CNY | 17.04% |
| 2022 FY | 1.65 Billion CNY | 43.15% |
| 2022 Q1 | 1.47 Billion CNY | 27.56% |
| 2022 Q4 | 1.65 Billion CNY | -4.77% |
| 2021 Q1 | 791.51 Million CNY | -3.27% |
| 2021 FY | 1.15 Billion CNY | 41.2% |
| 2021 Q2 | 849.39 Million CNY | 7.31% |
| 2021 Q4 | 1.15 Billion CNY | 1.24% |
| 2021 Q3 | 1.14 Billion CNY | 34.36% |
| 2020 FY | 818.26 Million CNY | 221.84% |
| 2020 Q1 | 588.54 Million CNY | 131.49% |
| 2020 Q2 | 758.62 Million CNY | 28.9% |
| 2020 Q3 | 932.09 Million CNY | 22.87% |
| 2020 Q4 | 818.26 Million CNY | -12.21% |
| 2019 Q1 | 116.99 Million CNY | 274.16% |
| 2019 FY | 254.24 Million CNY | 478.47% |
| 2019 Q2 | 285.18 Million CNY | 143.76% |
| 2019 Q3 | 300.39 Million CNY | 5.33% |
| 2019 Q4 | 254.24 Million CNY | -15.36% |
| 2018 Q2 | 82.51 Million CNY | 49.73% |
| 2018 FY | -67.17 Million CNY | -2.32% |
| 2018 Q4 | -67.17 Million CNY | -147.34% |
| 2018 Q3 | 141.89 Million CNY | 71.96% |
| 2018 Q1 | 55.11 Million CNY | 183.94% |
| 2017 Q4 | -65.65 Million CNY | -227.01% |
| 2017 FY | -65.65 Million CNY | 73.31% |
| 2017 Q3 | 51.69 Million CNY | 170.49% |
| 2017 Q2 | -73.32 Million CNY | 39.76% |
| 2017 Q1 | -121.72 Million CNY | 50.52% |
| 2016 Q4 | -245.98 Million CNY | 16.88% |
| 2016 Q2 | 266.83 Million CNY | -24.51% |
| 2016 Q1 | 353.48 Million CNY | -12.83% |
| 2016 FY | -245.98 Million CNY | -160.66% |
| 2016 Q3 | -295.94 Million CNY | -210.91% |
| 2015 Q3 | 464.97 Million CNY | 1.5% |
| 2015 Q2 | 458.09 Million CNY | 18.04% |
| 2015 Q1 | 388.07 Million CNY | 48.6% |
| 2015 FY | 405.51 Million CNY | 55.28% |
| 2015 Q4 | 405.51 Million CNY | -12.79% |
| 2014 Q4 | 261.15 Million CNY | -27.19% |
| 2014 FY | 261.15 Million CNY | 11265.72% |
| 2014 Q2 | 300.16 Million CNY | 107.8% |
| 2014 Q1 | 144.44 Million CNY | 6186.39% |
| 2014 Q3 | 358.68 Million CNY | 19.5% |
| 2013 Q2 | -134.55 Million CNY | 21.47% |
| 2013 Q4 | 2.29 Million CNY | 107.66% |
| 2013 Q3 | -30 Million CNY | 77.7% |
| 2013 FY | 2.29 Million CNY | 100.73% |
| 2013 Q1 | -171.33 Million CNY | 45.61% |
| 2012 Q1 | -527.68 Million CNY | 9.55% |
| 2012 FY | -315.02 Million CNY | 46.0% |
| 2012 Q2 | -419.98 Million CNY | 20.41% |
| 2012 Q3 | -339.09 Million CNY | 19.26% |
| 2012 Q4 | -315.02 Million CNY | 7.1% |
| 2011 Q3 | -553.47 Million CNY | -820.87% |
| 2011 Q2 | 76.77 Million CNY | 0.0% |
| 2011 Q4 | -583.39 Million CNY | -5.41% |
| 2011 FY | -583.39 Million CNY | -810.76% |
| 2010 FY | 82.08 Million CNY | 47.32% |
| 2010 Q4 | 82.08 Million CNY | 0.0% |
| 2009 FY | 55.71 Million CNY | -25.23% |
| 2008 FY | 74.52 Million CNY | 0.0% |